Trial of Gemcitabine_Capecitabine Versus Gemcitabine_Carboplatin in Breast Cancer
Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
Gemcitabine plus carboplatin in recurrent or metastatic breast cancer is a recommended scheme
in National Comprehensive Cancer Network (NCCN) guideline. gemcitabine in combination with
capecitabine is also effective in Metastatic Breast Cancer (MBC) in some clinical study with
small sample.
Phase:
Phase 3
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital